AI Article Synopsis
- * Molecular studies have identified altered pathways in these tumors, including the SHH pathway, which is activated by GLI1 overexpression.
- * Research shows that arsenic trioxide (ATO) can inhibit the growth of these tumors by suppressing GLI1, suggesting it could be a promising new treatment option for improving patient outcomes.
Article Abstract
Rhabdoid tumors are highly aggressive tumors occurring in infants and very young children. Despite multimodal and intensive therapy prognosis remains poor. Molecular analyses have uncovered several deregulated pathways, among them the CDK4/6-Rb-, the WNT- and the Sonic hedgehog (SHH) pathways. The SHH pathway is activated in rhabdoid tumors by GLI1 overexpression. Here, we demonstrate that arsenic trioxide (ATO) inhibits tumor cell growth of malignant rhabdoid tumors in vitro and in a mouse xenograft model by suppressing Gli1. Our data uncover ATO as a promising therapeutic approach to improve prognosis for rhabdoid tumor patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ijc.28719 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!